Aligos Therapeutics Raises $84M Via Equity At 7% Discount

by Vandana Singh, Benzinga Editor

July 1, 2021 7:25 AM | 1 min read |

Aligos Therapeutics Inc ALGS has priced a previously announced underwritten public offering of 4.4 million shares at $19 per share, representing a discount of 7% from the last close price of $20.3 on Wednesday.
The gross proceeds will be approximately $83.6 million.
Underwriters have an option to purchase up to an additional 660,000 shares.
The offering will close by July 6.
J.P. Morgan, Jefferies, and Piper Sandler are acting as the joint book-running managers for the offering. Cantor is acting as a lead manager for the offering.
Recently, the company announced preliminary data in healthy volunteers from Phase 1a/b multi-part trial of Aligos' S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPS) compound ALG-010133.
Price Action: ALGS shares closed at $20.3 on Wednesday.